Cuorips Inc.
Stock Price Chart
2026/08/19 UpdatedPrice Trend
2026/08/19 UpdatedPrice & Trading Details
2026/08/19 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥38M | ¥23M | ¥175M | ¥212M |
| Gross Profit | ¥21M | ¥10M | ¥168M | ¥130M |
| Operating Income | -¥450M | -¥588M | -¥590M | -¥1,081M |
| Pretax Income | -¥450M | -¥588M | -¥590M | -¥1,081M |
| Net Income | -¥452M | -¥632M | -¥644M | -¥1,023M |
| EPS | -¥59.94 | -¥85.86 | -¥80.52 | - |
| Operating Margin | -1,176.75% | -2,547.34% | -336.90% | -509.23% |
| Balance Sheet | ||||
| Total Assets | ¥3,587M | ¥6,185M | ¥5,742M | ¥5,123M |
| Total Equity | ¥3,454M | ¥5,982M | ¥5,527M | ¥4,750M |
| Total Liabilities | ¥134M | ¥202M | ¥215M | ¥373M |
| Cash | ¥2,942M | ¥5,561M | ¥4,595M | ¥3,653M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 96.27% | 96.73% | 96.26% | 92.72% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥402M | -¥451M | -¥813M | -¥1,060M |
| Investing CF | -¥9M | -¥35M | -¥120M | -¥35M |
| Financing CF | ¥11M | ¥3,125M | ¥145M | ¥204M |
| Free CF | -¥412M | -¥487M | -¥902M | -¥1,110M |
| Efficiency | ||||
| ROE | -13.09% | -10.57% | -11.66% | -21.53% |
| ROA | -12.60% | -10.22% | -11.22% | -19.96% |
Latest IR Information
-
Upward Revision of Full-Year Earnings Forecast | July 2026
Qualips has revised its full-year consolidated earnings forecast for the fiscal year ending March 2027 upward, projecting sales of 540 million yen and net profit of 570 million yen. The adjustments are due to the reimbursement price decision for Rehart...
Read more -
Rehart Insurance Reimbursement Price Determination ｜ July 22, 2026
Qualips has approved the insurance reimbursement price of 53,200,000 yen for RehartⓇ, scheduled for insurance listing on September 1, 2026. It is actively expanding sales domestically and internationally.
Read more -
Expansion of regenerative medicine business using cardiac cell sheets and progress in research and development
Qualips reports progress in regenerative medicine business using cardiac cell sheets and research advancements. Aiming for approvals domestically and internationally and advancing research contracts to create next-generation medical innovations.
Read more -
Ideas and Policies Regarding the Reduction of Investment Units
Discloses the current status of consideration for reducing the investment unit. No specific timing for concrete measures is determined; decision will be continued to be examined in light of stock price, market conditions, shareholder composition, and cost-effectiveness.
Read more -
Financial Results Explanation Materials for the Fiscal Year Ending March 2026
Read more
Latest News (5 items)
Company Information
About
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.
